Sequential and/or combination therapy with anti‐CTLA4 and anti‐PD1/anti‐PDL1 led to an almost threefold incidence of hypophysitis compared to either monotherapy, while only one of 120 patients receiving anti‐CTLA4 monotherapy developed primary hypothyroidism. The gene discussed is CTLA4; the disease is Primary hypothyroidism.